chufangao/CTO huggingface dataset:
Clinical trial NCT03060473: Treatment of ppROM With Erythromycin vs. Azithromycin Trial
Official title: TREAT: Treatment of ppROM With Erythromycin vs. Azithromycin Trial
Acronym: TREAT
Sponsor: The University of Texas Medical Branch, Galveston (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Patient population that meets study criteria is insufficient to continue project in a reasonable amount of time. To continue is futile in resources, staff time, and effort.
Enrollment: 21.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-02-23
Primary completion date: 2023-12-08
Completion date: 2023-12-08
Limitations and caveats: No data collected. The protocol was closed early due to low accrual and deemed futile.
Plan to share individual participant data: NO
Clinical trial NCT04037241: Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases
Official title: A Randomized Open-Label Phase 2b Study of Hepatic Infusions of Anti-CEA CAR-T Cells Alternating With Systemic Chemotherapy Versus Chemotherapy Alone In Patients With Liver Metastases Due To CEA-Expressing Pancreatic Adenocarcinoma
Sponsor: Sorrento Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Sponsor terminated
Enrollment: 0.0 (ACTUAL)
Number of arms: 8.0
Start date: 2021-11-01
Primary completion date: 2022-01-01
Completion date: 2022-01-01
Clinical trial NCT04478994: A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Official title: A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics, and Explore Efficacy of TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Poor enrollment
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-17
Primary completion date: 2022-11-29
Completion date: 2022-12-08
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Clinical trial NCT04450316: Low-dose Naltrexone for Bladder Pain Syndrome
Official title: Low-dose Naltrexone for Bladder Pain Syndrome: A Randomized Placebo-controlled Prospective Pilot Trial
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: Study temporarily suspended awaiting research personnel to resume recruitment
Enrollment: 40.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2020-10-08
Primary completion date: 2024-07-31
Completion date: 2024-10-31
Plan to share individual participant data: NO
IPD sharing description: Should the study result be positive or promising, we would undertake a larger trial at which point we can reassess the sharing of IPD.
Clinical trial NCT03898180: Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
Official title: A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 487.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-06
Primary completion date: 2021-07-26
Completion date: 2024-05-20
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT04764383: Histaminergic Basis of Fatigue in Multiple Sclerosis
Official title: Histaminergic Basis of Fatigue in Multiple Sclerosis
Sponsor: University of Miami (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Withdrawn as more data drug analysis is recommended before the study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-01-01
Primary completion date: 2022-10-30
Completion date: 2022-10-30
Plan to share individual participant data: NO
Clinical trial NCT02853071: Efficacy and Safety of Estracyt® in Metastatic Breast Cancer
Official title: Efficacy and Safety of Estracyt® in Metastatic Breast Cancer Hormonal Estrogen Receptor (HER 2) Negative, Hormone Receptor (HR) Positive.
Acronym: BEST
Sponsor: Centre Hospitalier Universitaire de Besancon (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: withdrawal industrial
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-01-31
Primary completion date: 2020-01-31
Completion date: 2020-01-31
Plan to share individual participant data: YES
IPD sharing description: The Committee shall meet twice a year
Clinical trial NCT02985021: Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
Official title: A Phase 2 Study of Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer and Germline or Somatic DNA Repair Deficiency
Sponsor: Seattle Institute for Biomedical and Clinical Research (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Competing studies
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-11-30
Primary completion date: 2021-04-30
Completion date: 2021-04-30
Baseline population: Patients with metastatic, resistant prostate cancer
Plan to share individual participant data: NO
Clinical trial NCT02753530: Study of Arimoclomol in Inclusion Body Myositis (IBM)
Official title: Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)
Sponsor: ZevraDenmark (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 152.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-08-16
Primary completion date: 2021-01-11
Completion date: 2021-01-11
Baseline population: Intention-to-treat (ITT) population. Patients randomized in error (1 patient in the arimoclomol group and 1 patient in the placebo group) were not included in the ITT population.
Clinical trial NCT03087448: Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Official title: A Phase I/II Study of Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Low Accrual
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-09-09
Primary completion date: 2022-04-30
Completion date: 2022-04-30
Plan to share individual participant data: NO
IPD sharing description: Individual participant data (IPD) will not be shared
Clinical trial NCT02640833: A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
Official title: A Phase 1b/2 Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Study Stopped
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-07-31
Primary completion date: 2020-01-31
Completion date: 2021-02-28
Clinical trial NCT03952377: Safety and Efficacy of SX600 Administered by Lumbosacral Transforaminal Epidural Injection for Radicular Pain
Official title: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase I/II, First-in-Human Study to Assess the Safety and Efficacy of Two Doses of SX600 Administered by Lumbosacral Transforaminal Epidural Injection in Patients With Radicular Pain Secondary to Lumbar Intervertebral Disc Herniation
Acronym: SALIENT
Sponsor: SpineThera Australia PTY LTD (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Due to the impact of COVID-19 and associated enrollment difficulties, the study was terminated with a total sample size of 56 randomized patients
Enrollment: 56.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-11-04
Primary completion date: 2022-02-21
Completion date: 2022-06-21
Baseline population: ITT Population
Limitations and caveats: Due to the impact of COVID-19 and associated enrollment difficulties, the study was terminated with a total sample size of 56 randomized patients.
Plan to share individual participant data: NO
Clinical trial NCT02974803: Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
Official title: A Phase II Study of Concurrent Dabrafenib and Trametinib With Stereotactic Radiation in the Management of Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
Sponsor: Canadian Cancer Trials Group (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Very slow accrual
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-02-09
Primary completion date: 2020-07-29
Completion date: 2020-07-29
Plan to share individual participant data: NO
Clinical trial NCT04723589: Restoration of Endothelial Integrity in Patients With COVID-19 (RELIC)
Official title: Restoration of Endothelial Integrity in Patients With COVID-19 (RELIC)
Acronym: RELIC
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Widespread vaccine availability
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-30
Primary completion date: 2021-04-30
Completion date: 2021-04-30
Plan to share individual participant data: NO
Clinical trial NCT05029245: IntraDermal Versus Intramuscular Comirnaty® Efficacy Study
Official title: The 8-week, Prospective, Randomized Controlled of IntraDermal Administration of Comirnaty® 6 Microgram Versus Intramuscular Comirnaty® 30 Microgram by 28 Days Interval Efficacy Study in Healthy Volunteer
Acronym: PRIDE
Sponsor: Rajavithi Hospital (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: No financial budget support
Enrollment: 0.0 (ACTUAL)
Number of arms: 8.0
Start date: 2021-08-31
Primary completion date: 2022-08-31
Completion date: 2022-10-31
Plan to share individual participant data: NO
Clinical trial NCT03373461: Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
Official title: An Adaptive Seamless Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 112.0 (ACTUAL)
Number of arms: 5.0
Start date: 2018-02-07
Primary completion date: 2020-12-29
Completion date: 2021-06-22
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03891264: Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain
Official title: Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain
Acronym: CBD
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Funding obtained to do a larger placebo-controlled trial
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-11-13
Primary completion date: 2020-11-23
Completion date: 2020-11-23
Plan to share individual participant data: YES
IPD sharing description: We will make this data available upon request
IPD time frame: Data will become available after 2 years
IPD access criteria: Researchers, not for commercial use
Clinical trial NCT04412707: A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients
Official title: A Randomized, Two-period, Cross-over, Phase 2 Study, Comparing Pharmacokinetics, and Assessing Safety and Tolerability of Peripheral and Central i.v. Administration of Melphalan Flufenamide (Melflufen) in RRMM Patients
Acronym: PORT
Sponsor: Oncopeptides AB (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The sponsor decided to terminate the study following an FDA request of a partial clinical hold.
Enrollment: 27.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-04
Primary completion date: 2021-06-02
Completion date: 2022-01-10
Baseline population: Full Analysis Set
Plan to share individual participant data: NO
Clinical trial NCT02564978: Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration
Official title: Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 37.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-12-14
Primary completion date: 2022-09-28
Completion date: 2023-03-08
Limitations and caveats: Potential disadvantages of study design (each participant eye serves as own control): long study period, requirement for participants to wait to begin treatment, and more complex interpretation of safety data. Potential limitations of study: discontinuation of study drug/study in number of participants (accounted for in sample size calculations), absence of assays to analyze microglial activity.
Plan to share individual participant data: NO
Clinical trial NCT04402580: Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome
Official title: Efficacy of Chimeric Monoclonal Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome and Development of Cell Biomarkers Predicting Outcome. The RTX 4 Trial.
Sponsor: Istituto Giannina Gaslini (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: due to unexpectedly high rate of relapse in the active comparator arm.
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-01
Primary completion date: 2020-08-31
Completion date: 2020-08-31
Plan to share individual participant data: YES
IPD sharing description: The completed study will be summarized in a final report that accurately and completely presents the study objectives, methods, results, limitations of the study, and interpretation of findings.~The first publication will be an in extenso publication of the results of the validation of the project.~The Authors of this study protocol will inform the contributing investigators in advance about any plans to publish or present data from this randomized controlled clinical trial. Any publications and presentations of the results (abstract in journals or newspapers, oral presentations, etc.), either in whole or in part, by Investigators or their representatives will require pre-submission review by the Authors of this study protocol.
Clinical trial NCT04296578: Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone
Official title: A Phase 1 Study Evaluating the Efficacy and Safety of Sodium Selenite in Combination With Abiraterone in Patients With Castrate Resistant Prostate Cancer Progressing on Abiraterone
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Study did not start
Enrollment: 0.0 (ACTUAL)
Number of arms: 6.0
Start date: 2020-10-31
Primary completion date: 2022-10-31
Completion date: 2023-10-31
Plan to share individual participant data: NO
Clinical trial NCT04152083: A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine
Official title: A Parallel Group, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing an Acute Attack of Migraine
Acronym: RELIEF
Sponsor: H. Lundbeck A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 485.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-07
Primary completion date: 2020-07-08
Completion date: 2020-07-08
Baseline population: Safety population included all participants who received eptinezumab or placebo.
Plan to share individual participant data: NO
Clinical trial NCT05029609: Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
Official title: A Phase 1b, Double-Blind, Randomized, Placebo Controlled, Multiple Ascending Dose Study of the Safety, Tolerability and Immune Effects of the Intranasal Anti-CD3 Monoclonal Antibody Foralumab in Primary and Secondary Progressive MS
Sponsor: Tiziana Life Sciences LTD (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Withdrawn due to business reasons
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-10-31
Primary completion date: 2022-11-30
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT04867785: A Study of LY3437943 in Participants With Type 2 Diabetes
Official title: A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 281.0 (ACTUAL)
Number of arms: 8.0
Start date: 2021-05-13
Primary completion date: 2022-07-08
Completion date: 2022-10-27
Baseline population: All randomized participants
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT06567457: Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults
Official title: Phase 3, Multi-center, Observer-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Monovalent Omicron XBB.1.5 Vaccine Administered as a Booster Dose to Adults Who Previously Received COVID-19 Vaccine
Sponsor: Clover Biopharmaceuticals AUS Pty Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: varients of COVID-19 has changed
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-10-31
Primary completion date: 2024-09-30
Completion date: 2024-10-31
Clinical trial NCT04652518: LYT-100 in Post-acute COVID-19 Respiratory Disease
Official title: A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease
Sponsor: PureTech (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Part A of the study was completed; Part B of the study was terminated
Enrollment: 185.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-12-11
Primary completion date: 2022-06-28
Completion date: 2022-07-18
Clinical trial NCT03782402: Cannabinoids for Taxane Induced Peripheral Neuropathy
Official title: The Effect of Dispensed Cannabis on Taxane Induced Peripheral Neuropathy
Sponsor: New York State Psychiatric Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Funding being sought
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-01
Primary completion date: 2021-08-30
Completion date: 2021-08-30
Limitations and caveats: Please note: this was a pilot study that was not funded for a full study.
Plan to share individual participant data: NO
Clinical trial NCT02304302: Down Syndrome Memantine Follow-up Study
Official title: Phase II Multicenter 16-Week Randomized Double Blind Placebo-Controlled Evaluation of the Efficacy, Tolerability and Safety of Memantine Hydrochloride on Enhancing the Cognitive Abilities of Adolescents and Young Adults With Down Syndrome
Sponsor: University Hospitals Cleveland Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 160.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-10-31
Primary completion date: 2020-07-22
Completion date: 2020-07-22
Clinical trial NCT04282590: A Study to Investigate the Safety and Efficacy of TRK-750 for the Treatment of Patients With CIPN (Chopin Study)
Official title: A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TRK-750 in Colorectal Cancer Patients With Chemotherapy-induced Peripheral Neuropathy Following Oxaliplatin-containing Chemotherapy in the Adjuvant Setting
Sponsor: Toray Industries, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: due to COVID-19 pandemic
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-30
Primary completion date: 2021-12-31
Completion date: 2021-12-31